The National Association of Chain Drug Stores RxImpact grassroots program sent action alerts to pharmacy advocates in Delaware and Louisiana regarding on state legislation on biosimilars and immunizations.


National Association of Chain Drug Stores, NACDS, RxImpact, grassroots program, Delaware, Louisiana, state legislation, biosimilars, immunizations, S.B. 118, biosimilar substitution, NACDS RxImpact, physician notification requirements, S.B. 600, pharmacy community




































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Retail News Breaks

NACDS RxImpact generates grassroots support on state bills

May 15th, 2014

ARLINGTON, Va. – The National Association of Chain Drug Stores RxImpact grassroots program sent action alerts to pharmacy advocates in Delaware and Louisiana regarding on state legislation on biosimilars and immunizations.

NACDS said Wednesday that in Delaware, RxIMPACT called on industry advocates to send messages to state legislators to oppose S.B. 118 if the bill continues to require doctors to be notified in instances of biosimilar substitution.

"It is critical you take action today before the Delaware House votes on Senate Bill 118 that could impose physician notification requirements on the substitution of biosimilar products deemed interchangeable by the Food and Drug Administration. NACDS RxImpact is calling on you to tell your legislators if these physician notification requirements are not eliminated from the bill in the amendment process, legislators must oppose SB 118," the Delaware action alert stated.

"Imposing physician notification requirements for the substitution of biosimilars would be redundant, as prescribers determine whether it is appropriate for pharmacists to substitute when issuing a prescription," the alert said. "Physician notification requirements that make the interchange of biosimilars more burdensome will only serve to limit the practice of substitution of more cost-effective biosimilar products. If enacted, this bill will impede greater savings for Delaware patients, health insurers and other third party payors, including Medicaid, while protecting the profits of innovator biotech firms that will financially benefit from statutory barriers making the interchange of biosimilars. Act today to halt these physician notification requirements with the amendment."

In Louisiana, RxImpact asked advocates to send messages to state representatives to support S.B. 600, a bill to expand pharmacists' authority to administer any immunization without a prescription or medical order to anyone 14 years and older.

"With your help, the pharmacy community could win expanded authority to administer immunizations in Louisiana. Make the NACDS RxImpact today by contacting your state representative to urge them to support SB 600 by Sen. [Fred] Mills," the Louisiana alert said. "If you are a pharmacist, intern or pharmacy student, or have operations in Louisiana, it is critical you contact your state representatives today."

More Retail News Breaks >>
Advertisement